| Description | CPS-11 (N-(Hydroxymethyl)thalidomide) is a Thalidomide analogue that has significant antitumor activity and exhibits a wider range of activity and highly potent effects on the MM (multiple myeloma) cell line. |
| In vitro | Confirming its ability to target tumor cells in the bone marrow microenvironment, CPS-11 abrogates the ability of bone marrow stromal cells (BMSCs) to induce proliferation of MM cells[1].Showing virtually no effect on the activation of p38 and only slight, transient activation of ATF2 and HSP27 (0-200 μM, 0 or 4 h), CPS-11 demonstrates its pharmacological behavior[2].At doses as high as 100 μM, CPS-11 (0-100 μM, 24 or 48 h) exhibits no toxicity to H157 cells, WT MEFs, or the p38α-/- MEFs[2].Furthermore, CPS-11 (50 μM, 24 or 48 h) does not induce apoptosis in H157 cells[2]. |
| Synonyms | CPS11, CPS 11, N-(Hydroxymethyl)thalidomide |
| molecular weight | 288.26 |
| Molecular formula | C14H12N2O5 |
| CAS | 145945-21-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (156.11 mM), Sonication is recommended. |
| References | 1. Aragon-Ching JB, et al. Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):167-74. 2. Warfel NA, et al. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3502-9. 3. Ge Y, et al. Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood. 2006 Dec 15;108(13):4126-35. 4. Nishiyama T, Ide T, Himes SR Jr, Ishizaka S, Araki T. Immunodiagnosis of human sparganosis mansoni by micro-chemiluminescence enzyme-linked immunosorbent assay. Trans R Soc Trop Med Hyg. 1994 Nov-Dec;88(6):663-5. PubMed PMID: 7886764. |